| 1 | Cardio‐renal‐metabolic disease in primary care setting | 5.1 | 8 | Citations (PDF) |
| 2 | Cardiovascular and renal outcomes with varying degrees of kidney disease in high‐risk people with type 2 diabetes: An epidemiological analysis of data from the AMPLITUDE‐O trial | 4.7 | 2 | Citations (PDF) |
| 3 | The current landscape for diabetes treatment: Preventing diabetes-associated CV risk | 1.6 | 11 | Citations (PDF) |
| 4 | β-Cell Function, Incretin Effect, and Glucose Kinetics in Response to a Mixed Meal in Patients With Type 2 Diabetes Treated With Dapagliflozin Plus Saxagliptin | 6.5 | 0 | Citations (PDF) |
| 5 | The role of incretin receptor agonists in the treatment of obesity | 4.7 | 13 | Citations (PDF) |
| 6 | Comparative renal outcomes of matched cohorts of patients with type 2 diabetes receiving SGLT2 inhibitors or GLP-1 receptor agonists under routine care | 8.6 | 17 | Citations (PDF) |
| 7 | Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment | 43.7 | 41 | Citations (PDF) |
| 8 | Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial | 25.2 | 22 | Citations (PDF) |
| 9 | Incretins and cardiovascular disease: to the heart of type 2 diabetes? | 8.6 | 22 | Citations (PDF) |
| 10 | Achieving Normoglycemia With Tirzepatide: Analysis of SURPASS 1–4 Trials | 6.5 | 30 | Citations (PDF) |
| 11 | MG53 marks poor beta cell performance and predicts onset of type 2 diabetes in subjects with different degrees of glucose tolerance. | 3.6 | 9 | Citations (PDF) |
| 12 | Basal weekly insulins: the way of the future! | 9.5 | 50 | Citations (PDF) |
| 13 | The incretin/glucagon system as a target for pharmacotherapy of obesity | 7.9 | 57 | Citations (PDF) |
| 14 | Challenges and opportunities in real‐world evidence on the renal effects of sodium‐glucose cotransporter‐2 inhibitors | 4.7 | 18 | Citations (PDF) |
| 15 | A few clinical features improve the prediction of mortality and cardiovascular outcomes in patients with type 2 diabetes | 2.1 | 0 | Citations (PDF) |
| 16 | Insulin discovery: A pivotal point in medical history | 9.5 | 24 | Citations (PDF) |
| 17 | Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial | 25.2 | 113 | Citations (PDF) |
| 18 | <i>SIRT1</i> rs7896005 polymorphism affects major vascular outcomes, not all‐cause mortality, in Caucasians with type 2 diabetes: A 13‐year observational study | 5.1 | 10 | Citations (PDF) |
| 19 | The IGFBP3/TMEM219 pathway regulates beta cell homeostasis | 13.9 | 45 | Citations (PDF) |
| 20 | Efficacy of Dulaglutide in a Patient With Type 2 Diabetes, High Cardiovascular Risk, and HIV: A Case Report | 4.1 | 4 | Citations (PDF) |
| 21 | The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review | 2.1 | 18 | Citations (PDF) |
| 22 | Insulin secretion and action affect glucose variability in the early stages of glucose intolerance | 5.1 | 15 | Citations (PDF) |
| 23 | Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis | 8.6 | 211 | Citations (PDF) |
| 24 | Short sleep duration and risk of gestational diabetes | 1.9 | 6 | Citations (PDF) |
| 25 | Brain effect of bariatric surgery in people with obesity | 3.2 | 17 | Citations (PDF) |
| 26 | Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) | 8.6 | 699 | Citations (PDF) |
| 27 | Exercise during pregnancy: how much active are pregnant women at risk of gestational diabetes despite few contraindications? | 1.9 | 8 | Citations (PDF) |
| 28 | Design and baseline characteristics of the <scp>AMPLITUDE‐O</scp> cardiovascular outcomes trial of efpeglenatide, a weekly glucagon‐like peptide‐1 receptor agonist | 4.7 | 18 | Citations (PDF) |
| 29 | Identification and management of cardiometabolic risk in subjects with schizophrenia spectrum disorders: A Delphi expert consensus study | 0.3 | 24 | Citations (PDF) |
| 30 | Predictors of post-traumatic complication of mild brain injury in anticoagulated patients: DOACs are safer than VKAs | 3.2 | 27 | Citations (PDF) |
| 31 | Translating iGlarLixi Evidence for the Management of Frequent Clinical Scenarios in Type 2 Diabetes | 3.5 | 8 | Citations (PDF) |
| 32 | Accuracy of 1-Hour Plasma Glucose During the Oral Glucose Tolerance Test in Diagnosis of Type 2 Diabetes in Adults: A Meta-analysis | 6.5 | 52 | Citations (PDF) |
| 33 | Impact of COVID-19 lockdown on glucose control of elderly people with type 2 diabetes in Italy | 6.2 | 34 | Citations (PDF) |
| 34 | From glucose lowering agents to disease/diabetes modifying drugs: a “SIMPLE” approach for the treatment of type 2 diabetes | 9.9 | 44 | Citations (PDF) |
| 35 | Diabetes and acute bacterial skin and skin structure infections | 6.2 | 44 | Citations (PDF) |
| 36 | Risk factors associated with postpartum impaired glucose regulation in women with previous gestational diabetes | 2.6 | 11 | Citations (PDF) |
| 37 | Bariatric surgery restores visual cortical plasticity in nondiabetic subjects with obesity | 3.2 | 9 | Citations (PDF) |
| 38 | Switching to <scp>iGlarLixi</scp> versus continuation of a daily or weekly glucagon‐like peptide‐1 receptor agonist (<scp>GLP</scp>‐1 <scp>RA</scp>) in insufficiently controlled type 2 diabetes: A <scp>LixiLan‐G</scp> trial subgroup analysis by HbA1c and <scp>GLP</scp>‐1 <scp>RA</scp> use at screening | 4.7 | 2 | Citations (PDF) |
| 39 | Breaking Therapeutic Inertia With Alirocumab in an 80-Year-Old Patient With Severe Hypercholesterolemia: A Case Report | 2.6 | 2 | Citations (PDF) |
| 40 | Telemonitoring, Telemedicine and Time in Range During the Pandemic: Paradigm Change for Diabetes Risk Management in the Post-COVID Future | 2.1 | 36 | Citations (PDF) |
| 41 | A fully implantable device for intraperitoneal drug delivery refilled by ingestible capsules | 14.3 | 55 | Citations (PDF) |
| 42 | Glycaemic control during the lockdown for COVID-19 in adults with type 1 diabetes: A meta-analysis of observational studies | 6.2 | 33 | Citations (PDF) |
| 43 | Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes | 43.7 | 667 | Citations (PDF) |
| 44 | Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials | 22.6 | 1,231 | Citations (PDF) |
| 45 | Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study | 6.5 | 7 | Citations (PDF) |
| 46 | COVID-19, Hyperglycemia, and New-Onset Diabetes | 6.5 | 260 | Citations (PDF) |
| 47 | Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial | 52.8 | 525 | Citations (PDF) |
| 48 | Patient-reported outcomes in elderly patients with type 2 diabetes mellitus treated with dual oral therapy: a multicenter, observational study from Italy | 2.2 | 3 | Citations (PDF) |
| 49 | Effects of treatment with metformin and/or sitagliptin on beta‐cell function and insulin resistance in prediabetic women with previous gestational diabetes | 4.7 | 26 | Citations (PDF) |
| 50 | Type 1 diabetes and COVID-19: The “lockdown effect” | 6.2 | 47 | Citations (PDF) |
| 51 | COVID-19 in people with diabetes: understanding the reasons for worse outcomes | 22.6 | 769 | Citations (PDF) |
| 52 | Guida pratica alla prevenzione e gestione dell’infezione da COVID-19 nelle persone con diabete | 0.0 | 1 | Citations (PDF) |
| 53 | Increase in endogenous glucose production with SGLT2 inhibition is attenuated in individuals who underwent kidney transplantation and bilateral native nephrectomy | 8.6 | 28 | Citations (PDF) |
| 54 | Bariatric and metabolic surgery during and after the COVID-19 pandemic: DSS recommendations for management of surgical candidates and postoperative patients and prioritisation of access to surgery | 22.6 | 153 | Citations (PDF) |
| 55 | Increase in Endogenous Glucose Production With SGLT2 Inhibition Is Unchanged by Renal Denervation and Correlates Strongly With the Increase in Urinary Glucose Excretion | 6.5 | 21 | Citations (PDF) |
| 56 | Review of methods for detecting glycemic disorders | 6.2 | 165 | Citations (PDF) |
| 57 | Diabetes and COVID-19: Risks, Management, and Learnings From Other National Disasters | 6.5 | 174 | Citations (PDF) |
| 58 | Efficacy and safety of once‐monthly efpeglenatide in patients with type 2 diabetes: Results of a phase 2 placebo‐controlled, 16‐week randomized dose‐finding study | 4.7 | 36 | Citations (PDF) |
| 59 | Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumab | 2.1 | 11 | Citations (PDF) |
| 60 | Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol | 9.9 | 27 | Citations (PDF) |
| 61 | Nesidioblastosis and Insulinoma: A Rare Coexistence and a Therapeutic Challenge | 4.1 | 16 | Citations (PDF) |
| 62 | Plasma N-Acetylaspartate Is Related to Age, Obesity, and Glucose Metabolism: Effects of Antidiabetic Treatment and Bariatric Surgery | 4.1 | 16 | Citations (PDF) |
| 63 | Impact of disease duration and β‐cell reserve on the efficacy of switching to <scp>iGlarLixi</scp> in adults with type 2 diabetes on glucagon‐like peptide‐1 receptor agonist therapy: Exploratory analyses from the <scp>LixiLan‐G</scp> trial | 4.7 | 11 | Citations (PDF) |
| 64 | Use of incretin-based medications: what do current international recommendations suggest with respect to GLP-1 receptor agonists and DPP-4 inhibitors? | 9.5 | 21 | Citations (PDF) |
| 65 | Effectiveness of dapagliflozin versus comparators on renal endpoints in the real world: A multicentre retrospective study | 4.7 | 37 | Citations (PDF) |
| 66 | Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies | 9.9 | 32 | Citations (PDF) |
| 67 | Inibitori di SGLT-2 e chetoacidosi euglicemica: conoscere per prevenire | 0.0 | 1 | Citations (PDF) |
| 68 | Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial | 6.5 | 76 | Citations (PDF) |
| 69 | Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial | 52.8 | 303 | Citations (PDF) |
| 70 | Cardiovascular Effects of Pioglitazone or Sulfonylureas According to Pretreatment Risk: Moving Toward Personalized Care | 4.2 | 11 | Citations (PDF) |
| 71 | A pre‐specified statistical analysis plan for the VERIFY study: Vildagliptin efficacy in combination with metformin for early treatment of T2DM | 4.7 | 8 | Citations (PDF) |
| 72 | Exenatide modulates visual cortex responses | 5.1 | 4 | Citations (PDF) |
| 73 | Glucose-lowering therapy and cardiovascular outcomes in patients with type 2 diabetes mellitus and acute coronary syndrome | 2.9 | 45 | Citations (PDF) |
| 74 | Factors influencing safe glucose-lowering in older adults with type 2 diabetes: A PeRsOn-centred ApproaCh To IndiVidualisEd (PROACTIVE) Glycemic Goals for older people | 2.0 | 37 | Citations (PDF) |
| 75 | Immune Checkpoint Blockade Anti–PD-L1 as a Trigger for Autoimmune Polyendocrine Syndrome | 0.3 | 57 | Citations (PDF) |
| 76 | Microvascular complications burden (nephropathy, retinopathy and peripheral polyneuropathy) affects risk of major vascular events and all-cause mortality in type 1 diabetes: a 10-year follow-up study | 9.9 | 62 | Citations (PDF) |
| 77 | Altered Visual Plasticity in Morbidly Obese Subjects | 3.6 | 27 | Citations (PDF) |
| 78 | Freestyle Libre trend arrows for the management of adults with insulin-treated diabetes: A practical approach | 2.6 | 23 | Citations (PDF) |
| 79 | Sustained 52‐week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes | 4.7 | 21 | Citations (PDF) |
| 80 | Albuminuric and non-albuminuric chronic kidney disease in type 1 diabetes: Association with major vascular outcomes risk and all-cause mortality | 2.6 | 17 | Citations (PDF) |
| 81 | Alirocumab vs usual lipid‐lowering care as add‐on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM‐DYSLIPIDEMIA randomized trial | 4.7 | 90 | Citations (PDF) |
| 82 | Oral glucose lowering with linagliptin and metformin compared with linagliptin alone as initial treatment in Asian patients with newly diagnosed type 2 diabetes and marked hyperglycemia: Subgroup analysis of a randomized clinical trial | 2.9 | 13 | Citations (PDF) |
| 83 | Practical strategies for improving outcomes in <scp>T2DM</scp>: <scp>T</scp>he potential role of pioglitazone and <scp>DPP4</scp> inhibitors | 4.7 | 19 | Citations (PDF) |
| 84 | Petition to replace current OGTT criteria for diagnosing prediabetes with the 1-hour post-load plasma glucose ≥ 155 mg/dl (8.6 mmol/L) | 6.2 | 94 | Citations (PDF) |
| 85 | Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial | 52.8 | 1,540 | Citations (PDF) |
| 86 | Pre-pregnancy obesity, gestational diabetes or gestational weight gain: Which is the strongest predictor of pregnancy outcomes? | 6.2 | 39 | Citations (PDF) |
| 87 | Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus—Rationale, design, and baseline characteristics | 3.0 | 81 | Citations (PDF) |
| 88 | Efficacy and safety of alirocumab in individuals with type 2 diabetes mellitus with or without mixed dyslipidaemia: Analysis of the ODYSSEY LONG TERM trial | 1.6 | 30 | Citations (PDF) |
| 89 | Influence of high density lipoprotein cholesterol levels on circulating monocytic angiogenic cells functions in individuals with type 2 diabetes mellitus | 9.9 | 6 | Citations (PDF) |
| 90 | Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study | 4.7 | 162 | Citations (PDF) |
| 91 | Type 2 Diabetes Mellitus. From the start – combination therapy | 1.2 | 3 | Citations (PDF) |
| 92 | Early Combination Therapy with Oral Glucose-Lowering Agents in Type 2 Diabetes | 11.8 | 30 | Citations (PDF) |
| 93 | Evidence for two distinct phenotypes of chronic kidney disease in individuals with type 1 diabetes mellitus | 8.6 | 44 | Citations (PDF) |
| 94 | Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial | 22.6 | 266 | Citations (PDF) |
| 95 | Efficacy and safety of alirocumab in insulin‐treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The <scp>ODYSSEY DM‐INSULIN</scp> randomized trial | 4.7 | 129 | Citations (PDF) |
| 96 | Gender difference in diabetes related excess risk of cardiovascular events: When does the ‘risk window’ open? | 2.6 | 17 | Citations (PDF) |
| 97 | A Fermented Whole Grain Prevents Lipopolysaccharides‐Induced Dysfunction in Human Endothelial Progenitor Cells | 4.6 | 34 | Citations (PDF) |
| 98 | Metabolic regulation of GLP-1 and PC1/3 in pancreatic α-cell line | 2.4 | 43 | Citations (PDF) |
| 99 | Ten Years of Vildagliptin | 2.6 | 0 | Citations (PDF) |
| 100 | Beliefs, Barriers, and Preferences of European Overweight Women to Adopt a Healthier Lifestyle in Pregnancy to Minimize Risk of Developing Gestational Diabetes Mellitus: An Explorative Study | 2.0 | 36 | Citations (PDF) |
| 101 | Efficacy and safety of linagliptin according to patient baseline characteristics: A pooled analysis of three phase 3 trials | 3.4 | 8 | Citations (PDF) |
| 102 | Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations | 6.5 | 809 | Citations (PDF) |
| 103 | Integrating medical and surgical therapies to optimize the outcomes of type 2 diabetes | 2.6 | 4 | Citations (PDF) |
| 104 | Linagliptin plus metformin in patients with newly diagnosed type 2 diabetes and marked hyperglycemia | 2.8 | 6 | Citations (PDF) |
| 105 | Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations | 2.6 | 139 | Citations (PDF) |
| 106 | 1h post-load blood glucose for detection of individuals at increased risk of diabetes and cardiovascular disease | 6.2 | 1 | Citations (PDF) |
| 107 | Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice | 9.9 | 47 | Citations (PDF) |
| 108 | Hospital incidental diagnosis of diabetes: A population study | 2.6 | 8 | Citations (PDF) |
| 109 | Dipeptidyl peptidase-4 inhibition in chronic kidney disease and potential for protection against diabetes-related renal injury | 3.4 | 44 | Citations (PDF) |
| 110 | Use of a basal-plus insulin regimen in persons with type 2 diabetes stratified by age and body mass index: A pooled analysis of four clinical trials | 2.0 | 15 | Citations (PDF) |
| 111 | Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: a Joint Statement by International Diabetes Organizations | 2.4 | 139 | Citations (PDF) |
| 112 | Access to emergency room for hypoglycaemia in people with diabetes | 5.1 | 15 | Citations (PDF) |
| 113 | Effect of diabetes on hospitalization for ischemic stroke and related in‐hospital mortality: a study in Tuscany, Italy, over years 2004–2011 | 5.1 | 32 | Citations (PDF) |
| 114 | New forms of insulin and insulin therapies for the treatment of type 2 diabetes | 22.6 | 96 | Citations (PDF) |
| 115 | Gender difference in diabetes-associated risk of first-ever and recurrent ischemic stroke | 2.6 | 38 | Citations (PDF) |
| 116 | Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: A meta-analysis of seven clinical trials | 3.4 | 63 | Citations (PDF) |
| 117 | Glucose Metabolism in High-Risk Subjects for Type 2 Diabetes Carrying the rs7903146<i>TCF7L2</i>Gene Variant | 4.2 | 16 | Citations (PDF) |
| 118 | The addition of E (Empowerment and Economics) to the ABCD algorithm in diabetes care | 2.6 | 18 | Citations (PDF) |
| 119 | Clinical Assessment of Individualized Glycemic Goals in Patients With Type 2 Diabetes: Formulation of an Algorithm Based on a Survey Among Leading Worldwide Diabetologists | 6.5 | 46 | Citations (PDF) |
| 120 | Cardiovascular and heart failure safety profile of vildagliptin: a meta‐analysis of 17 000 patients | 4.7 | 97 | Citations (PDF) |
| 121 | Physical activity, depressed mood and pregnancy worries in European obese pregnant women: results from the DALI study | 2.5 | 38 | Citations (PDF) |
| 122 | How much weight are women gaining during pregnancy? An Italian cohort study | 1.9 | 5 | Citations (PDF) |
| 123 | GLP-1 receptor agonists in type 1 diabetes: a proof-of-concept approach | 2.4 | 16 | Citations (PDF) |
| 124 | Influence of dietary fat and carbohydrates proportions on plasma lipids, glucose control and low-grade inflammation in patients with type 2 diabetes—The TOSCA.IT Study | 3.5 | 53 | Citations (PDF) |
| 125 | Effect of streptozotocin in a case of glucagon-secreting malignant islets-cell tumor | 3.0 | 0 | Citations (PDF) |
| 126 | Insulin receptors on circulating blood cells from patients with pancreatogenic diabetes: a comparison with type I diabetes and normal subjects | 3.0 | 7 | Citations (PDF) |
| 127 | High blood ketone body concentration in Type 2 non-insulin dependent diabetic patients | 3.0 | 28 | Citations (PDF) |
| 128 | Left ventricular mass in type 2 diabetes mellitus. A study employing a simple ECG index: The Cornell voltage | 3.0 | 3 | Citations (PDF) |
| 129 | Dipeptidyl peptidase 4 (DPP-4) inhibitors and their role in Type 2 diabetes management | 3.0 | 53 | Citations (PDF) |
| 130 | Gestational diabetes, inflammation, and late vascular disease | 3.0 | 26 | Citations (PDF) |
| 131 | Pituitary autoimmunity in patients with diabetes mellitus and other endocrine disorders | 3.0 | 9 | Citations (PDF) |
| 132 | Grain and Bean Lysates Improve Function of Endothelial Progenitor Cells from Human Peripheral Blood: Involvement of the Endogenous Antioxidant Defenses | 2.4 | 31 | Citations (PDF) |
| 133 | OP44 ORAL GLUCOSE LOWERING WITH LINAGLIPTIN PLUS METFORMIN COMPARED WITH LINAGLIPTIN ALONE AS INITIAL TREATMENT IN ASIAN PATIENTS WITH NEWLY DIAGNOSED TYPE 2 DIABETES AND MARKED HYPERGLYCEMIA | 6.2 | 0 | Citations (PDF) |
| 134 | Cardiovascular risk assessment in low-resource settings | 2.3 | 82 | Citations (PDF) |
| 135 | Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future | 52.8 | 1,479 | Citations (PDF) |
| 136 | Insulin degludec/insulin aspart combination for the treatment of type 1 and type 2 diabetes | 2.7 | 13 | Citations (PDF) |
| 137 | Q192R Paraoxonase (PON)1 Polymorphism, Insulin Sensitivity, and Endothelial Function in Essential Hypertensive Men | 3.2 | 6 | Citations (PDF) |
| 138 | Efficacy and safety of linagliptin in subjects with type 2 diabetes mellitus and poor glycemic control: Pooled analysis of data from three placebo-controlled phase III trials | 2.6 | 17 | Citations (PDF) |
| 139 | Hyperglycemia and Vascular Metabolic Memory: Truth or Fiction? | 5.4 | 44 | Citations (PDF) |
| 140 | Elevated 1-Hour Postload Plasma Glucose Levels Identify Subjects With Normal Glucose Tolerance but Impaired β-Cell Function, Insulin Resistance, and Worse Cardiovascular Risk Profile: The GENFIEV Study | 4.2 | 109 | Citations (PDF) |
| 141 | Vergleich von Dapagliflozin und Glipizid als Add-on-Therapie bei Typ-2-Diabetikern mit unzureichender Blutzuckerkontrolle unter Metformin | 0.2 | 11 | Citations (PDF) |
| 142 | Individualized glycaemic targets and pharmacotherapy in type 2 diabetes | 2.9 | 40 | Citations (PDF) |
| 143 | Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin | 2.7 | 22 | Citations (PDF) |
| 144 | Early detection of left ventricular dysfunction in diabetes mellitus patients with normal ejection fraction, stratified by BMI: A preliminary speckle tracking echocardiography study | 0.6 | 15 | Citations (PDF) |
| 145 | Measurement of Insulin Resistance In Vivo | 11.8 | 6 | Citations (PDF) |
| 146 | Cytochrome P450 2J2 Polymorphism in Healthy Caucasians and those with Diabetes Mellitus | 0.9 | 7 | Citations (PDF) |
| 147 | Metabolic Syndrome | 2.6 | 16 | Citations (PDF) |
| 148 | Cardiovascular Prevention in Subjects with Impaired Fasting Glucose or Impaired Glucose Tolerance | 2.6 | 9 | Citations (PDF) |
| 149 | 2009 SIPREC Consensus Document – Executive Summary | 2.6 | 0 | Citations (PDF) |
| 150 | 1-Hour OGTT Plasma Glucose as a Marker of Progressive Deterioration of Insulin Secretion and Action in Pregnant Women | 2.0 | 13 | Citations (PDF) |
| 151 | Evidence for a Role of Frataxin in Pancreatic Islets Isolated from Multi-Organ Donors with and Without Type 2 Diabetes Mellitus | 1.9 | 12 | Citations (PDF) |
| 152 | Long-Term (5 Years) Efficacy and Safety of Pancreas Transplantation Alone in Type 1 Diabetic Patients | 1.2 | 46 | Citations (PDF) |
| 153 | Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial | 52.8 | 314 | Citations (PDF) |
| 154 | Response Letter to D. Singh‐Franco et al. | 4.7 | 0 | Citations (PDF) |
| 155 | Telecare Provides Comparable Efficacy to Conventional Self-Monitored Blood Glucose in Patients with Type 2 Diabetes Titrating One Injection of Insulin Glulisine—the ELEONOR Study | 4.8 | 49 | Citations (PDF) |
| 156 | European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR) | 2.3 | 5,448 | Citations (PDF) |
| 157 | Pathogenetic Mechanisms and Cardiovascular Risk | 6.5 | 38 | Citations (PDF) |
| 158 | PPARG2 Pro12Ala and ADAMTS9 rs4607103 as “insulin resistance loci” and “insulin secretion loci” in Italian individuals. The GENFIEV study and the Verona Newly Diagnosed Type 2 Diabetes Study (VNDS) 4 | 2.4 | 34 | Citations (PDF) |
| 159 | Linagliptin for the treatment of type 2 diabetes | 2.2 | 6 | Citations (PDF) |
| 160 | Metabolic syndrome in subjects at high risk for type 2 diabetes: The genetic, physiopathology and evolution of type 2 diabetes (GENFIEV) study | 3.4 | 18 | Citations (PDF) |
| 161 | Management of type 2 diabetes: new and future developments in treatment | 52.8 | 488 | Citations (PDF) |
| 162 | Results of Pancreas Transplantation Alone with Special Attention to Native Kidney Function and Proteinuria in Type 1 Diabetes Patients | 3.0 | 34 | Citations (PDF) |
| 163 | Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin | 6.5 | 514 | Citations (PDF) |
| 164 | Metabolic Memory and Individual Treatment Aims in Type 2 Diabetes – Outcome-Lessons Learned from Large Clinical Trials | 3.0 | 54 | Citations (PDF) |
| 165 | Blood Glucose Control and Coronary Heart Disease | 0.8 | 8 | Citations (PDF) |
| 166 | Serum gamma‐glutamyltransferase levels are related to insulin sensitivity and secretion in subjects with abnormal glucose regulation | 5.1 | 6 | Citations (PDF) |
| 167 | The A1C and ABCD of glycaemia management in type 2 diabetes: a physician's personalized approach | 5.1 | 106 | Citations (PDF) |
| 168 | Early Left Ventricular Mechanics Abnormalities in Prehypertension: A Two-Dimensional Strain Echocardiography Study | 2.0 | 85 | Citations (PDF) |
| 169 | Oxidative stress in response to high glucose levels in endothelial cells and in endothelial progenitor cells | 2.6 | 47 | Citations (PDF) |
| 170 | G-protein-coupled receptor 40 (GPR40) expression and its regulation in human pancreatic islets: The role of type 2 diabetes and fatty acids | 3.4 | 59 | Citations (PDF) |
| 171 | A Common Polymorphism in the Monocyte Chemoattractant Protein-1 (MCP-1) Gene Regulatory Region Influences MCP-1 Expression and Function of Isolated Human Pancreatic Islets | 0.7 | 10 | Citations (PDF) |
| 172 | Functional and Survival Analysis of Isolated Human Islets | 0.7 | 7 | Citations (PDF) |
| 173 | P4.07 DIFFERENT IMPACT OF HYPERTENSION AND TYPE 2 DIABETES ON AORTIC, CAROTID AND PERIPHERAL VASCULAR STIFFNESS | 1.6 | 0 | Citations (PDF) |
| 174 | Physical activity and dietary habits during pregnancy: effects on glucose tolerance | 1.8 | 17 | Citations (PDF) |
| 175 | Changing the Treatment Paradigm for Type 2 Diabetes | 6.5 | 36 | Citations (PDF) |
| 176 | Soluble CD40 Ligand Levels in Essential Hypertensive Men: Evidence of a Possible Role of Insulin Resistance | 2.0 | 14 | Citations (PDF) |
| 177 | Is There Evidence That Oral Hypoglycemic Agents Reduce Cardiovascular Morbidity/Mortality? Yes | 6.5 | 27 | Citations (PDF) |
| 178 | How Do We Define Cure of Diabetes? | 6.5 | 916 | Citations (PDF) |
| 179 | Lack of association between TGF- -1 genotypes and microalbuminuria in essential hypertensive men | 0.8 | 11 | Citations (PDF) |
| 180 | Lower fasting blood glucose, glucose variability and nocturnal hypoglycaemia with glargine vs NPH basal insulin in subjects with Type 1 diabetes | 3.4 | 40 | Citations (PDF) |
| 181 | The non-peptidyl low molecular weight radical scavenger IAC protects human pancreatic islets from lipotoxicity | 3.5 | 28 | Citations (PDF) |
| 182 | Serum gamma-glutamyltransferase is not associated to peripheral arterial disease in type 2 diabetic patients: Cross-sectional findings | 1.6 | 2 | Citations (PDF) |
| 183 | Epigenetic regulation of PPARGC1A in human type 2 diabetic islets and effect on insulin secretion | 8.6 | 457 | Citations (PDF) |
| 184 | β-cell failure in type 2 diabetes mellitus | 5.4 | 53 | Citations (PDF) |
| 185 | Optimizing management of metabolic syndrome to reduce risk: focus on life-style | 3.2 | 27 | Citations (PDF) |
| 186 | Modulation of palmitic acid‐induced cell death by ergothioneine: Evidence of an anti‐inflammatory action | 5.3 | 49 | Citations (PDF) |
| 187 | Non-traditional markers of atherosclerosis potentiate the risk of coronary heart disease in patients with type 2 diabetes and metabolic syndrome | 3.4 | 17 | Citations (PDF) |
| 188 | Hyperinsulinemia and insulin resistance are independently associated with plasma lipids, uric acid and blood pressure in non-diabetic subjects. The GISIR database | 3.4 | 67 | Citations (PDF) |
| 189 | Early impairment of left ventricular function in hypercholesterolemia and its reversibility after short term treatment with rosuvastatin | 1.6 | 36 | Citations (PDF) |
| 190 | β-cell apoptosis in type 2 diabetes: quantitative and functional consequences | 3.6 | 76 | Citations (PDF) |
| 191 | Early Subclinical Atherosclerosis in Women With Previous Gestational Diabetes Mellitus | 6.5 | 35 | Citations (PDF) |
| 192 | Insulin resistance and lipid disorders | 0.8 | 13 | Citations (PDF) |
| 193 | Metabolic Syndrome and Vascular Alterations in Normotensive Subjects at Risk of Diabetes Mellitus | 6.9 | 57 | Citations (PDF) |
| 194 | Peripheral wave reflection and endothelial function in untreated essential hypertensive patients with and without the metabolic syndrome | 2.3 | 22 | Citations (PDF) |
| 195 | Dysglycaemia in non-diabetic hypertensive patients: comparison of the impact of two different classifications of impaired fasting glucose on the cardiovascular risk profile | 2.9 | 8 | Citations (PDF) |
| 196 | Coxsackie B4 virus infection of β cells and natural killer cell insulitis in recent-onset type 1 diabetic patients | 7.6 | 548 | Citations (PDF) |
| 197 | Treating the metabolic syndrome | 1.9 | 60 | Citations (PDF) |
| 198 | Cystatin C and Estimates of Renal Function: Searching for a Better Measure of Kidney Function in Diabetic Patients | 1.1 | 158 | Citations (PDF) |
| 199 | Correspondence Between the International Diabetes Federation Criteria for Metabolic Syndrome and Insulin Resistance in a Cohort of Italian Nondiabetic Caucasians: The GISIR database | 6.5 | 4 | Citations (PDF) |
| 200 | Lack of association between endothelial nitric oxide synthase gene polymorphisms, microalbuminuria and endothelial dysfunction in hypertensive men | 2.3 | 23 | Citations (PDF) |
| 201 | Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in diabetic and healthy subjects | 3.6 | 120 | Citations (PDF) |
| 202 | Insulin secretion defects of human type 2 diabetic islets are corrected in vitro by a new reactive oxygen species scavenger | 3.6 | 52 | Citations (PDF) |
| 203 | Non-traditional cardiovascular risk factors contribute to peripheral arterial disease in patients with type 2 diabetes | 6.2 | 25 | Citations (PDF) |
| 204 | High insulin levels impair intracellular receptor trafficking in human cultured myoblasts | 6.2 | 12 | Citations (PDF) |
| 205 | Doxazosin in metabolically complicated hypertension | 1.9 | 9 | Citations (PDF) |
| 206 | When and how to restore β-cell function? | 0.2 | 2 | Citations (PDF) |
| 207 | Effects of C-peptide on isolated human pancreatic islet cells | 5.1 | 19 | Citations (PDF) |
| 208 | ß‐cell function and anti‐diabetic pharmacotherapy | 5.1 | 71 | Citations (PDF) |
| 209 | Type 2 diabetes mellitus: focus on new treatments and special populations | 2.1 | 3 | Citations (PDF) |
| 210 | Left Ventricular Function in Normotensive Young Adults With Well-Controlled Type 1 Diabetes Mellitus | 1.9 | 47 | Citations (PDF) |
| 211 | Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors | 2.6 | 16 | Citations (PDF) |
| 212 | Glucose tolerance is negatively associated with circulating progenitor cell levels | 8.6 | 97 | Citations (PDF) |
| 213 | Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes | 10.7 | 725 | Citations (PDF) |
| 214 | The metabolic syndrome | 9.4 | 14 | Citations (PDF) |
| 215 | Early impairment of β-cell function and insulin sensitivity characterizes normotolerant Caucasian women with previous gestational diabetes | 3.4 | 9 | Citations (PDF) |
| 216 | Transcription factors of beta-cell differentiation and maturation in isolated human islets: Effects of high glucose, high free fatty acids and type 2 diabetes | 3.4 | 9 | Citations (PDF) |
| 217 | ACE gene insertion/deletion polymorphism modulates capillary permeability in hypertension | 6.4 | 14 | Citations (PDF) |
| 218 | Inhaled insulins: the present and future of diabetes therapy | 2.2 | 6 | Citations (PDF) |
| 219 | α-Adducin and angiotensin-converting enzyme polymorphisms in hypertension: evidence for a joint influence on albuminuria | 2.3 | 17 | Citations (PDF) |
| 220 | Disappearance of Nephrotic Syndrome in Type 1 Diabetic Patients Following Pancreas Transplant Alone | 1.2 | 21 | Citations (PDF) |
| 221 | Pancreas transplant alone has beneficial effects on retinopathy in type 1 diabetic patients | 8.6 | 111 | Citations (PDF) |
| 222 | Cystatin C as a marker of renal function immediately after liver transplantation | 2.6 | 57 | Citations (PDF) |
| 223 | The vascular effects of doxazosin in hypertension complicated by metabolic syndrome | 1.2 | 21 | Citations (PDF) |
| 224 | Unlocking the opportunity of tight glycaemic control. Far from goal | 4.7 | 7 | Citations (PDF) |
| 225 | Effects of pancreas-kidney transplantation on diabetic retinopathy | 2.1 | 92 | Citations (PDF) |
| 226 | Effects of prolonged in vitro exposure to sulphonylureas on the function and survival of human islets | 2.6 | 74 | Citations (PDF) |
| 227 | Functional and morphological alterations of mitochondria in pancreatic beta cells from type 2 diabetic patients | 8.6 | 351 | Citations (PDF) |
| 228 | Chlorthalidone Improves Endothelial-Mediated Vascular Responses in Hypertension Complicated by Nondiabetic Metabolic Syndrome | 2.7 | 19 | Citations (PDF) |
| 229 | Ninety-Five Percent Insulin Independence Rate 3 Years After Pancreas Transplantation Alone With Portal-Enteric Drainage | 0.7 | 13 | Citations (PDF) |
| 230 | Successful Solitary Pancreas Transplantation With Portal-Enteric Drainage Following Unsuccessful Islet Cell Transplantation | 0.7 | 1 | Citations (PDF) |
| 231 | Prevalence of the metabolic syndrome among Italian adults according to ATP III definition | 3.4 | 168 | Citations (PDF) |
| 232 | Expression and activity of CYP2E1 in circulating lymphocytes are not altered in diabetic individuals | 9.4 | 10 | Citations (PDF) |
| 233 | Continually high insulin levels impair Akt phosphorylation and glucose transport in human myoblasts | 9.5 | 41 | Citations (PDF) |
| 234 | Activation of the Hexosamine Pathway Leads to Phosphorylation of Insulin Receptor Substrate-1 on Ser307 and Ser612 and Impairs the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Insulin Biosynthetic Pathway in RIN Pancreatic β-Cells | 2.6 | 66 | Citations (PDF) |
| 235 | Rosiglitazone plus metformin: combination therapy for Type 2 diabetes | 2.2 | 13 | Citations (PDF) |
| 236 | Targeting Insulin Resistance and β-Cell Dysfunction: The Role of Thiazolidinediones | 4.8 | 18 | Citations (PDF) |
| 237 | Pancreatic Islets from Type 2 Diabetic Patients Have Functional Defects and Increased Apoptosis That Are Ameliorated by Metformin | 4.2 | 322 | Citations (PDF) |
| 238 | Exogenous and Endogenous Postprandial Lipid Abnormalities in Type 2 Diabetic Patients with Optimal Blood Glucose Control and Optimal Fasting Triglyceride Levels | 4.2 | 87 | Citations (PDF) |
| 239 | Serum Haptoglobin: A Novel Marker of Adiposity in Humans | 4.2 | 112 | Citations (PDF) |
| 240 | Insulin Resistance Is Independently Associated With Postprandial Alterations of Triglyceride-Rich Lipoproteins in Type 2 Diabetes Mellitus | 6.3 | 74 | Citations (PDF) |
| 241 | Lack of evidence for the 1484insG variant at the 3'-UTR of the protein tyrosine phosphatase 1B (PTP1B) gene as a genetic determinant of diabetic nephropathy development in type 1 diabetic patients | 0.8 | 2 | Citations (PDF) |
| 242 | Low-Grade Inflammation and Microalbuminuria in Hypertension | 6.3 | 94 | Citations (PDF) |
| 243 | A simplified technique for the en bloc procurement of abdominal organs that is suitable for pancreas and small-bowel transplantation | 1.8 | 58 | Citations (PDF) |
| 244 | Improved insulin secretory function and reduced chemotactic properties after tissue culture of islets from type 1 diabetic patients | 5.1 | 25 | Citations (PDF) |
| 245 | Beta- and Alpha-Cell Dysfunction in Type 2 Diabetes | 1.9 | 102 | Citations (PDF) |
| 246 | Pancreas transplant alone | 0.7 | 10 | Citations (PDF) |
| 247 | Solitary pancreas transplantation: preliminary findings about early reduction of proteinuria in incipient or evident diabetic type I nephropathy | 0.7 | 4 | Citations (PDF) |
| 248 | Kidney and pancreas transplants in Jehovah's witnesses: ethical and practical implications | 0.7 | 19 | Citations (PDF) |
| 249 | An alternative and simple method to consistently prepare viable isolated human islets for clinical transplantation | 0.7 | 6 | Citations (PDF) |
| 250 | Portal enteric–drained solitary pancreas transplantation without surveillance biopsy: is it safe? | 0.7 | 5 | Citations (PDF) |
| 251 | Simultaneous pancreas-kidney transplantation is improved by living kidney donation program | 0.7 | 2 | Citations (PDF) |
| 252 | Single-Center, open, prospective, randomized pilot study comparing cyclosporine versus tacrolimus in simultaneous Pancreas-Kidney transplantation | 0.7 | 7 | Citations (PDF) |
| 253 | Abnormal capillary permeability and endothelial dysfunction in hypertension with comorbid Metabolic Syndrome | 1.6 | 63 | Citations (PDF) |
| 254 | PANCREAS PRESERVATION WITH UNIVERSITY OF WISCONSIN AND CELSIOR SOLUTIONS: A SINGLE-CENTER, PROSPECTIVE, RANDOMIZED PILOT STUDY | 1.2 | 73 | Citations (PDF) |
| 255 | Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARγ<sub>2</sub> in the modulation of insulin secretion | 3.1 | 138 | Citations (PDF) |
| 256 | In situ protein Kinase C activity is increased in cultured fibroblasts from Type 1 diabetic patients with nephropathy | 8.6 | 19 | Citations (PDF) |
| 257 | Hyperglycaemia and cardiovascular risk | 2.4 | 16 | Citations (PDF) |
| 258 | Six-month efficacy of benfluorex vs. placebo or metformin in diet-failed type 2 diabetic patients | 2.4 | 28 | Citations (PDF) |
| 259 | Identification of cathepsin K as a novel marker of adiposity in white adipose tissue | 4.2 | 63 | Citations (PDF) |
| 260 | Elevated non-esterified fatty acids impair nitric oxide independent vasodilation, in humans: evidence for a role of inwardly rectifying potassium channels | 1.6 | 27 | Citations (PDF) |
| 261 | Prevalence and risk factors for gestational diabetes assessed by universal screening | 6.2 | 159 | Citations (PDF) |
| 262 | Type 2 diabetes: simple, dual or multiple pathogenetic defects? | 0.2 | 0 | Citations (PDF) |
| 263 | Reducing insulin resistance with metformin: the evidence today | 3.6 | 222 | Citations (PDF) |
| 264 | Microalbuminuria, a parameter independent of metabolic influences in hypertensive men | 2.3 | 11 | Citations (PDF) |
| 265 | Solitary pancreas transplantation in wolfram syndrome1. | 1.2 | 4 | Citations (PDF) |
| 266 | Pancreas transplant alone determines early improvement of cardiovascular risk factors and cardiac function in type 1 diabetic patients1 | 1.2 | 45 | Citations (PDF) |
| 267 | Effect of sodium intake on blood pressure and albuminuria in Type 2 diabetic patients: the role of insulin resistance | 8.6 | 134 | Citations (PDF) |
| 268 | Early Improvement of Unstable Diabetic Retinopathy After Solitary Pancreas Transplantation | 6.5 | 29 | Citations (PDF) |
| 269 | Insulin Secretory Function Is Impaired in Isolated Human Islets Carrying the Gly972->Arg IRS-1 Polymorphism | 4.4 | 104 | Citations (PDF) |
| 270 | Lipotoxicity in Human Pancreatic Islets and the Protective Effect of Metformin | 4.4 | 161 | Citations (PDF) |
| 271 | Biochemical and ultrasound tests for early diagnosis of active neuro-osteoarthropathy (NOA) of the diabetic foot | 6.2 | 30 | Citations (PDF) |
| 272 | A telemedicine support for diabetes management: the T-IDDM project | 4.7 | 109 | Citations (PDF) |
| 273 | Universal screening and intensive metabolic management of gestational diabetes: cost-effectiveness in Italy | 2.4 | 27 | Citations (PDF) |
| 274 | In search of normoglycaemia in diabetes: controlling postprandial glucose | 3.2 | 82 | Citations (PDF) |
| 275 | Combination of continuous subcutaneous infusion of insulin and octreotide in Type 1 diabetic patients | 6.2 | 15 | Citations (PDF) |
| 276 | Continuous subcutaneous insulin infusion in a patient with partial endocrine pancreatic graft function | 0.7 | 0 | Citations (PDF) |
| 277 | Cardiovascular risk factors in recipients of successful kidney-pancreas transplantation | 0.7 | 0 | Citations (PDF) |
| 278 | Glucose intolerance and diabetes in recipients of kidney graft: comparison of old and new ADA and WHO criteria | 0.7 | 0 | Citations (PDF) |
| 279 | The importance of first-phase insulin secretion: implications for the therapy of type 2 diabetes mellitus | 5.1 | 210 | Citations (PDF) |
| 280 | Effect of obesity and insulin resistance on resting and glucose-induced thermogenesis in man | 3.2 | 57 | Citations (PDF) |
| 281 | Brain function rescue effect of lactate following hypoglycaemia is not an adaptation process in both normal and Type I diabetic subjects | 8.6 | 70 | Citations (PDF) |
| 282 | Mechanisms of acute and chronic hypoglycemic action of gliclazide | 2.4 | 11 | Citations (PDF) |
| 283 | Plasma Free Fatty Acids and Endothelium-Dependent Vasodilation: Effect of Chain-Length and Cyclooxygenase Inhibition | 4.2 | 64 | Citations (PDF) |
| 284 | Studies on the mass action effect of glucose in NIDDM and IDDM: evidence for glucose resistance | 8.6 | 88 | Citations (PDF) |
| 285 | Gliclazide potentiates suppression of hepatic glucose production in non—insulin-dependent diabetic patients | 9.5 | 15 | Citations (PDF) |
| 286 | Intracellular lactate- and pyruvate-interconversion rates are increased in muscle tissue of non-insulin-dependent diabetic individuals. | 10.7 | 82 | Citations (PDF) |
| 287 | Unresectable hepatocellular carcinoma in cirrhosis | 2.3 | 72 | Citations (PDF) |
| 288 | Insulin resistance and diabetes mellitus | 2.6 | 37 | Citations (PDF) |
| 289 | Insulin Sensitivity Is Not Impaired In Mexican-American Women Without a Family History Of Diabetes | 6.5 | 9 | Citations (PDF) |
| 290 | What therapy do our NIDDM patients need? Insulin releasers | 6.2 | 12 | Citations (PDF) |
| 291 | Improvement of Basal Hepatic Glucose Production ana Fasting Hyperglycemia of Type I Diabetic Patients Treated With Human Recombinant Ultralente Insulin | 6.5 | 4 | Citations (PDF) |
| 292 | Effect of sustained physiologic hyperinsulinaemia and hyperglycaemia on insulin secretion and insulin sensitivity in man | 8.6 | 294 | Citations (PDF) |
| 293 | Mechanisms of fasting hypoglycemia and concomitant insulin resistance in insulinoma patients | 9.5 | 28 | Citations (PDF) |
| 294 | Body Composition Study in The Elderly: Comparison Between Tritium Dilution Method and Dual Photon Absorptiometry | 2.8 | 9 | Citations (PDF) |
| 295 | Short-term effects of metformin on insulin sensitivity and sodium homeostasis in essential hypertensives | 2.3 | 14 | Citations (PDF) |
| 296 | Characterization of cellular defects of insulin action in type 2 (non-insulin-dependent) diabetes mellitus. | 10.7 | 161 | Citations (PDF) |
| 297 | Transmembrane glucose transport in skeletal muscle of patients with non-insulin-dependent diabetes. | 10.7 | 135 | Citations (PDF) |
| 298 | Retrospective analysis of daily glucose profile in type 1 diabetic patients with continuous subcutaneous insulin infusion (CSII) | 6.2 | 2 | Citations (PDF) |
| 299 | The contribution of hyperglycaemia and hypoinsulinaemia to the insulin resistance of streptozotocin-diabetic rats | 8.6 | 41 | Citations (PDF) |
| 300 | Glucose Turnover and Recycling in Diabetes Secondary to Total Pancreatectomy: Effect of Glucagon Infusion* | 4.2 | 22 | Citations (PDF) |
| 301 | Partial recovery of insulin secretion and action after combined insulin-sulfonylurea treatment in Type 2 (non-insulin-dependent) diabetic patients with secondary failure to oral agents | 8.6 | 25 | Citations (PDF) |
| 302 | Insulin regulation of glucose and lipid metabolism in massive obesity | 8.6 | 58 | Citations (PDF) |
| 303 | Obesity and insulin resistance in humans: A dose-response study | 9.5 | 348 | Citations (PDF) |
| 304 | ‘Do-it-yourself’ insulin pump. Case report | 0.3 | 1 | Citations (PDF) |
| 305 | Metabolic control during total parenteral nutrition: Use of an artificial endocrine pancreas | 9.5 | 14 | Citations (PDF) |
| 306 | Hyperglucagonemia and insulin-mediated glucose metabolism. | 10.7 | 86 | Citations (PDF) |
| 307 | Hyperalaninaemia is an early feature of diabetes secondary to total pancreatectomy | 8.6 | 8 | Citations (PDF) |
| 308 | Effects of Insulin Treatment on Ketone Body Production and Carnitine-Palmitoyl-Transferase (CPT) Activity in the Isolated Perfused Liver from Streptozotocin Diabetic Rats | 1.9 | 3 | Citations (PDF) |
| 309 | Effect of insulin replacement on intermediary metabolism in diabetes secondary to pancreatectomy | 8.6 | 28 | Citations (PDF) |
| 310 | Metabolic effects of moderate alcohol intake with meals in insulin-dependent diabetics controlled by artificial endocrine pancreas (AEP) and in normal subjects | 9.5 | 17 | Citations (PDF) |
| 311 | The Presence of Retinopathy in Patients with Secondary Diabetes Following Pancreatectomy or Chronic Pancreatitis | 6.5 | 44 | Citations (PDF) |
| 312 | Insulin Resistance in Cushing’s Syndrome* | 4.2 | 146 | Citations (PDF) |
| 313 | The relationship between alanine and ketone body in vivo | 9.5 | 11 | Citations (PDF) |
| 314 | The antiketogenic effect of alanine in normal man: Evidence for an alanine-ketone body cycle | 9.5 | 24 | Citations (PDF) |
| 315 | Glycerophosphate acyltransferase activity in perfused liver of normal and hyperlipemic rats: Glucagon effect | 2.4 | 4 | Citations (PDF) |
| 316 | Glucagon levels and ketogenesis in human diabetes following total or partial pancreatectomy and severe chronic pancreatitis | 0.3 | 15 | Citations (PDF) |
| 317 | Continuous subcutaneous insulin infusion and multiple dose insulin injections in Type 1 diabetic pregnant women: a case-control study | 1.9 | 10 | Citations (PDF) |
